18 results about "Kidney cell" patented technology

The application discloses a kind of kidney cell cancer patient prognosis risk prediction methods based on multi-modal deep learning.The present application processes whole field digital pathology section (WSI) image and pathological diagnosis report by deep learning algorithm, extracts text features using natural language processing model, extracts image features using computer vision model and ABMIL network, and carries out multi-modal feature fusion through Cross-attention Transformer network, and finally outputs the survival risk curve of patient changes with time in combination with Weibull survival function, for assisting doctor to carry out more accurate prognosis evaluation and survival analysis.

Provided herein are, inter alia, extracellular products (e.g., vesicles such as microvesicles, e.g., exosomes) produced by renal cells (such as bioactive renal cells, e.g., selected renal cells). Methods of altering components (such as miRNAs or proteins) of vesicles produced by cells, as well as methods of producing vesicles comprising various compounds are also included. Also provided are diagnostic and treatment methods

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

This invention discloses a cell line capable of inhibiting African swine fever virus (ASFV) replication and its construction method, relating to the field of biotechnology. The construction method includes the following steps: knocking out the ANXA1 gene in African green monkey kidney cells to construct a stably inherited ANXA1 gene knockout cell line; this ANXA1 gene knockout cell line is the cell line capable of inhibiting ASFV replication. The cell line provided by this invention can significantly inhibit ASFV replication. Compared to existing porcine cell lines, this cell line has a clear background, is free from endogenous porcine pathogen contamination, and can be passaged indefinitely, solving the problems of cumbersome porcine cell preparation and large batch-to-batch variations. Simultaneously, this cell line provides a targeted cell model for studying the replication mechanism of ASFV and establishes an efficient evaluation system for high-throughput screening of anti-ASFV drugs, thereby facilitating the development of research related to ASFV prevention and control.

The application discloses an sgRNA capable of effectively editing a pig CCR5 gene and application thereof, and is premised on an sgRNA capable of specifically recognizing a pig CCR5 gene in a pig genome, and successfully constructs a pig fetal fibroblast cell, a pig kidney cell line PK15 cell line and a pig 3D4 / 21 cell line with EGFP site-directed integration by using CRISPR / Cas9 mediated gene knock-in technology, and the results show that the EGFP gene can be stably and efficiently expressed in the three kinds of cells or cell lines. The application provides more site selection and reference for gene function research, gene modified pig research and development.

The application discloses methyl phenolic compounds, a preparation method and application thereof. Six new methyl phenolic compounds are separated from the skin of eleocharis tuberosa, and the compounds all show good inhibitory activity on alpha-glucosidase, and are stronger than the clinical first-line drug acarbose. The inhibitory activity of compound 3 is the best, enzyme kinetics research shows that the compound 3 plays a role as a reversible mixed inhibitor, ADME predicts that the compound 3 has good drug properties, including high gastrointestinal absorption and no CYP450 enzyme inhibition. The cytotoxicity experiment shows that the six compounds have no obvious growth inhibition on human embryonic kidney cells HEK293 at a concentration of 100 muM, and have good safety. The compounds can be combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition, and are used for preparing a health care product for reducing blood sugar or a drug for treating diabetes. The preparation method is simple, easy to operate, suitable for industrial production, and is helpful to the high-value reuse of the skin of eleocharis tuberosa.

A method and system for assessing a histopathological cause of kidney graft dysfunction in a subject following kidney transplantation is disclosed. The method comprises the steps of: a) generating one or more images of the native fluorescence emission from one or more exfoliated kidney cells obtained from a urine sample from the subject in a plurality of distinctive spectral channels, b) calculating, for each urinary exfoliated kidney cell, quantitative features of the autofluorescence signals in said one or more images, c) applying a feature selection methodology to the quantitative features to generate a set of optimised quantitative features; and d) applying a classification method to the optimised quantitative features to produce a multispectral profile for differentiating the histopathological cause of kidney graft dysfunction in the subject from a plurality of histopathological causes of kidney graft dysfunction.

This invention provides a human embryonic kidney (HEK) cell line or its progeny, wherein the cell line is deposited with accession numbers selected from CCTCC NO: C202372, CCTCC NO: C2023129, CCTCC NO: C2023130, CCTCC NO: C2023131, CCTCC NO: C2023132, CCTCC NO: C2023133, and CCTCC NO: C2023134. This invention also provides a method for preparing rAAV using the said cell line or its progeny, or a kit for preparing rAAV containing the said cell line or its progeny.

Methods for identifying enriched heterogeneous renal cell populations with therapeutic potential, enriched heterogeneous renal cell populations with therapeutic potential, and uses thereof.

This invention discloses the application of Terminalia chebula in the prevention and treatment of Ichthyophthirius multifiliis (white spot disease) in aquatic animals. Toxicity experiments on grass carp kidney cells (CIK) showed that the maximum non-toxic concentration (NDC) of the aqueous extract of Terminalia chebula against CIK cells was 500 μg / mL. The inhibition of Ichthyophthirius multifiliis predator survival by the aqueous extract was dose-dependent, and the predator mortality rate reached 100% at a concentration of 100 mg / L (μg / mL). Furthermore, the median lethal concentration (LD50) of the aqueous extract against Ichthyophthirius multifiliis predators was calculated to be 14.577 mg / L. This invention is the first to propose the application of Terminalia chebula in inhibiting the survival rate of Ichthyophthirius multifiliis predators in fish at a non-toxic concentration to cells, providing a novel drug for the prevention and treatment of Ichthyophthirius multifiliis infection in aquatic animals. Terminalia chebula is a natural medicinal plant, environmentally friendly, and has the advantages of reducing the risk of drug residues.

The presently disclosed subject matter relates to compositions and methods for generating stable human embryonic kidney 293 (HEK-293) cell lines for adeno-associated virus (AAV) production.

The present application relates to the technical field of genetic engineering, and specifically discloses a 293T cell line stably expressing ruminant SLAM protein, a construction method and application thereof, which comprises introducing an HA tag at the 3' end of a ruminant SLAM gene to obtain a SLAM-HA target gene, connecting the SLAM-HA target gene to a lentivirus vector CD513B-Cherry, transforming DH5a competent cells, extracting a positive plasmid to obtain a lentivirus vector plasmid; mixing the lentivirus vector plasmid with an auxiliary plasmid, and respectively transfecting 293T cells to obtain packaged SLAM lentivirus; and transducing the SLAM lentivirus into human renal epithelial cells to obtain a human renal epithelial cell line stably expressing ruminant SLAM protein. The present application successfully constructs a cell line stably expressing ruminant SLAM protein, which can obviously mediate the infection and proliferation of PPRV, and has potential for preparing a vaccine.

The application discloses an African green monkey kidney cell clone and application thereof in detection of chicken newcastle disease virus, and particularly relates to the technical field of biological product detection. The detection method specifically comprises the following steps: (1) cell plating: taking prepared VERO-K6 cell suspension, taking a certain amount of the cell suspension into a dish, and then adding the cell suspension into a cell culture plate by using a cell plating gun; the cell culture plate is placed into a culture box and cultured until the cells grow into a dense monolayer; (2) sample dilution: taking a certain amount of chicken newcastle disease virus liquid into a 10 ‑1 EP tube, oscillating and uniformly mixing the virus liquid, taking an equal amount of virus liquid from a 10 ‑1 centrifugal tube into a 10 ‑2 centrifugal tube, and sequentially performing 10 times dilution; (3) sample adding; and (4) culture: placing the cell culture plate into the culture box, culturing, recording the number of effective lesion holes, and calculating TCID 50 according to the Reed-Muench method. Compared with the existing chicken newcastle disease virus detection method, the application has the advantages of low detection cost, simple detection process, short detection period and the like.

Methods of identifying an enriched heterogeneous renal cell population having therapeutic potential, enriched heterogeneous renal cell populations having therapeutic potential and uses for same.

This invention belongs to the field of biomedical technology and relates to the application of IIA compounds in the preparation of drugs for the treatment of kidney injury-related diseases. Through cell experiments and animal experiments, it has been confirmed that IIA-12 can reduce apoptosis levels, regulate immune inflammatory responses, and improve renal function in in vivo and in vitro models of ischemia-reperfusion kidney injury. IIA-12 can reduce renal tubular damage caused by AKI, improve renal tubular epithelial cell apoptosis and inflammation, and promote renal cell function repair.

The present application relates to a kind of double crosslinking intelligent response hydrogel, the double crosslinking intelligent response hydrogel includes drug-loaded nanoparticles and hydrogel network;The drug-loaded nanoparticles include mesoporous polydopamine, triphenylphosphine and drug, and the drug includes Icaritin;The hydrogel network includes mussel mucin, oxidized dextran and methacrylated silk fibroin.Preparation method includes the following steps: the preparation of mesoporous polydopamine;The preparation of nanoparticle;Nanoparticle drug loading;The preparation of oxidized dextran;The preparation of methacrylated silk fibroin and the preparation of double crosslinking intelligent response hydrogel.The double crosslinking intelligent response hydrogel of the present application can realize kidney cell mitochondria precise targeting, controllable drug release and have fast hemostasis and tissue filling function, and give consideration to the demand of drug intervention iron death and postoperative tissue repair.

This invention relates to a method and application of the inhibitor EHop-016 for inhibiting porcine epidemic diarrhea virus (PEDV) infection in vitro. EHop-016 can be used to prepare antiviral drugs for inhibiting PEDV infection. In this invention, during the in vitro infection of African green monkey kidney cells (Vero) with PEDV, the addition of 4 μmol / L EHop-016 significantly reduced the viral load, protein expression level, RNA content, and viral titer of PEDV in the EHop-016-treated group compared to the control group without EHop-016, indicating that this inhibitor can be used to inhibit porcine epidemic diarrhea virus infection in vitro.